Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Works matching IS 11707690 AND DT 2008 AND VI 26 AND IP 7
Results: 9
1
2
The Author's Reply.
- Published in:
- PharmacoEconomics, 2008, v. 26, n. 7, p. 567, doi. 10.2165/00019053-200826070-00004
- By:
- Publication type:
- Article
3
Recent National and Regional Drug Reforms in Sweden: Implications for Pharmaceutical Companies in Europe.
- Published in:
- PharmacoEconomics, 2008, v. 26, n. 7, p. 537, doi. 10.2165/00019053-200826070-00001
- By:
- Publication type:
- Article
4
Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes: A Systematic Review on Content and Adherence to Guidelines.
- Published in:
- PharmacoEconomics, 2008, v. 26, n. 7, p. 569, doi. 10.2165/00019053-200826070-00005
- By:
- Publication type:
- Article
5
Pharmaceutical Risk-Sharing Agreements.
- Published in:
- PharmacoEconomics, 2008, v. 26, n. 7, p. 551, doi. 10.2165/00019053-200826070-00002
- By:
- Publication type:
- Article
6
Generic Entry, Reformulations and Promotion of SSRIs in the US.
- Published in:
- PharmacoEconomics, 2008, v. 26, n. 7, p. 603, doi. 10.2165/00019053-200826070-00007
- By:
- Publication type:
- Article
7
Future Drug Prices and Cost-Effectiveness Analyses.
- Published in:
- PharmacoEconomics, 2008, v. 26, n. 7, p. 589, doi. 10.2165/00019053-200826070-00006
- By:
- Publication type:
- Article
8
Does Direct-to-Consumer Advertising of Antidepressants Lead to a Net Social Benefit?
- Published in:
- 2008
- By:
- Publication type:
- Editorial
9
Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK.
- Published in:
- PharmacoEconomics, 2008, v. 26, n. 7, p. 617, doi. 10.2165/00019053-200826070-00008
- By:
- Publication type:
- Article